More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$311648811
EPS
-2.01
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
0.730266
Previous close
$3.02
Today's open
$3.02
Day's range
$2.89 - $3.29
52 week range
$1.92 - $6.42
show more
CEO
Carole S. Ben-Maimon
Employees
71
Headquarters
Bala Cynwyd, PA
Exchange
NASDAQ Global Market
Shares outstanding
103882937
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update
BALA CYNWYD, Pa., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter 2026 operating and financial results.
GlobeNewsWire • Nov 16, 2026

Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich's Ataxia
Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the underlying cause of FA Submission follows FDA alignment on key elements of the BLA package for submission, including willingness to consider skin frataxin as a potential novel surrogate endpoint Previously reported open label data showed sustained increases in skin frataxin with directional clinical improvements observed in multiple outcomes relative to a natural history reference population Patients currently enrolling in FORWARD-FA, the global confirmatory Phase 3 study for nomlabofusp BALA CYNWYD, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced completion of its rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of nomlabofusp for the treatment of patients with Friedreich's ataxia (FA).
GlobeNewsWire • Nov 9, 2026

Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research
BALA CYNWYD, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that previously disclosed interim clinical data from the ongoing open-label study of long-term daily nomlabofusp administration, and new plasma lipid and gene expression analyses in study participants with Friedreich's ataxia (FA) will be presented as part of three poster presentations at the upcoming International Congress for Ataxia Research (ICAR) 2026 being held November 10–13, 2026, in Atlanta, Georgia.
GlobeNewsWire • Nov 5, 2026

Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
BALA CYNWYD, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will participate in a fireside chat and 1x1 investor meetings at the Guggenheim 3rd Annual Healthcare Innovation Conference, taking place in Boston, MA from November 9-11, 2026.
GlobeNewsWire • Nov 4, 2026

3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
Small-cap stocks tend to fly under the radar. Often in startup stages, these companies can lack analyst coverage, be overlooked by institutional investors, and be illiquid due to low average trading volume.
MarketBeat • Oct 10, 2026

Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Larimar (LRMR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks Investment Research • Oct 5, 2026

Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to Carole Ben-Maimon, M.D., Larimar's Chief Executive Officer. Mr. Harlow joins Larimar with more than 25 years of commercial, operational and business development experience across the biopharmaceutical industry.
GlobeNewsWire • Sep 29, 2026

5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
Zacks Investment Research • Sep 14, 2026

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update
BALA CYNWYD, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its second quarter 2026 operating and financial results.
GlobeNewsWire • Aug 4, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PRNewsWire • Jul 23, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Larimar Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.